Tardive Dyskinesia: Moving Management Forward

Target Audience
This educational activity is directed toward psychiatrists, neurologists, nurse practitioners, physician assistants, primary care clinicians, and other health care professionals involved in the management of TD.

Activity Overview
Tardive dyskinesia (TD) is a hyperkinetic movement disorder associated with dopamine receptor–blocking agents. Spontaneous movements involving the mouth and tongue are the most common manifestations; however, TD can also affect the arms, legs, trunk, and respiratory muscles. TD remains a persistent problem, despite the use of atypical or second- and third-generation antipsychotics, which carry a lower risk of developing TD. Early detection of TD is crucial, since the discontinuation of offending agents gives the best chance of recovery. Current treatment consists of vesicular monoamine transporter 2 (VMAT2) inhibitors.

During this edition of Clinical Consultations™, 3 expert faculty will discuss risk factors for and identification of TD as well as treatment recommendations according to current guidelines. They will then discuss the latest evidence on emerging therapies and conclude with the potential impact of clinical trial data on patients’ lives.

Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
• Assess recent clinical trial data for current and emerging therapies for TD
• Evaluate recent guidelines for the treatment of TD
• Apply recent data to individualize management plans for patients with TD